Core Viewpoint - Fudan Zhangjiang (01349.HK) announced that it will hold a board meeting on October 30, 2025, to review and approve the unaudited performance for the third quarter ending September 30, 2025, for the company and its subsidiaries [1] Summary by Category - Company Announcement - The board meeting is scheduled for October 30, 2025 [1] - The meeting will focus on the unaudited performance for the third quarter ending September 30, 2025 [1] - Financial Reporting - The performance report will include results from both the company and its subsidiaries [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 董事會會議通告 上海復旦張江生物醫藥股份有限公司（「本公司」）之董事會（「董事會」）謹 此公佈，將於二零二五年十月三十日（星期四）舉行董事會會議，以審議及通過 （其中包括）本公司及其附屬公司截至二零二五年九月三十日止第三季度之未經審 核業績及其發佈。 承董事會命 趙大君 主席 - 1 - 於本公告刊發日期，董事會包括以下人士： 趙大君先生（執行董事） 中國·上海 二零二五年十月十五日 * 僅供識別 - 2 - 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先生（獨立非執行董事） 林兆榮先生（獨立非執行董事） 徐培龍先生（獨立非執行董事） ...

Core Viewpoint - Fudan Zhangjiang's subsidiary failed to obtain approval from the National Medical Products Administration for its drug Obecholic Acid Tablets, which is intended for the treatment of Primary Biliary Cholangitis (PBC) [1] Company Summary - The drug Obecholic Acid Tablets is classified as a Class 3 chemical generic drug and acts as a Farnesoid X receptor agonist to regulate bile acid metabolism for PBC treatment [1] - Fudan Zhangjiang completed the human bioequivalence study for the drug in July 2020 and submitted the application for market approval in October last year, which was accepted [1] - The company invested a total of 125 million yuan (approximately 17.5 million USD) in the drug development, which has been fully accounted for in the respective financial periods [1] Financial Performance - In the first half of the year, the company reported revenue of 390 million yuan (approximately 54.5 million USD), a year-on-year decrease of 4.42% [1] - The net profit attributable to the parent company was 5.71 million yuan (approximately 800,000 USD), representing a significant year-on-year decline of 91.89% [1]

Core Viewpoint - Fudan Zhangjiang (688505) has entered into two structured deposit agreements with Bank of China, utilizing temporarily idle funds from its A-share public offering, totaling RMB 170 million [1] Group 1: Stock Performance - As of October 14, 2025, Fudan Zhangjiang's stock closed at RMB 9.02, down 0.88% from the previous trading day [1] - The stock opened at RMB 9.09, reached a high of RMB 9.19, and a low of RMB 8.97, with a trading volume of RMB 56.688 million and a turnover rate of 0.88% [1] Group 2: Structured Deposit Agreements - The company has signed two structured deposit agreements with Bank of China, with a total investment of RMB 170 million [1] - Agreement I involves an investment of RMB 40 million for 63 days, linked to the GBP/USD spot exchange rate, with an expected annualized return of 0.5500%-1.7000% [1] - Agreement II involves an investment of RMB 130 million for 78 days, linked to the EUR/USD spot exchange rate, with an expected annualized return of 0.3500%-1.5575% [1] Group 3: Disclosure and Approval - The transactions are disclosed under listing rules and are exempt from independent shareholder approval [1] - The board believes the transactions are conducted on normal commercial terms and are in the overall interest of the company and its shareholders [1]

Core Viewpoint - The failure of the generic drug application for Obeticholic Acid by Fudan Zhangjiang highlights the high-risk nature of the pharmaceutical industry, particularly in the context of drug approvals and market entry [2][3]. Company Summary - Fudan Zhangjiang Biopharmaceutical Co., Ltd. announced that its subsidiary, Taizhou Fudan Zhangjiang, received a notice of disapproval from the National Medical Products Administration for its application of Obeticholic Acid tablets, which were intended for the treatment of Primary Biliary Cholangitis (PBC) [2]. - The company had invested approximately 125 million yuan in the development of Obeticholic Acid tablets as of the announcement date [4]. - The disapproval was attributed to the lack of sufficient evidence supporting the drug's benefits over risks, particularly due to the original drug's performance in the market, which has raised concerns about severe liver damage [4][6]. - Despite the setback, the company plans to continue increasing its R&D investments and accelerate the progress of other projects to maintain revenue contributions and enhance its core competitiveness [6]. Industry Summary - The pharmaceutical industry is characterized by high risks, with many companies facing challenges in drug development and approval processes [4]. - The original drug, Obeticholic Acid, has faced scrutiny and regulatory actions, including a recommendation for withdrawal of its market authorization by the European Medicines Agency and a voluntary market withdrawal in the U.S. [3]. - Other companies, such as Zai Lab, have also encountered difficulties with FXR agonists, indicating broader challenges within this segment of the pharmaceutical market [5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購中國銀行結構性存款產品 認購結構性存款產品 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議 I 及中國銀行結構性存款產品協議 II，同意以 A 股公開發行所得暫時閑置募集資金向中國銀行認購總金額為人民幣 1.70 億元的結構 性存款產品。 上市規則的涵義 在訂立中國銀行結構性存款產品協議時，就中國銀行結構性存款產品協議項下產品的認購金額而 言，一項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市 規則第 14 章，该交易構成本公司之須予披露的交易，須遵守上市規則第 14 章有關申報及公告之 規定，惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議 I 及中國銀行結構性存款產品協議 II， 同意以 A 股公開發行所得暫時閑置募集資金向中國銀行認購總金額為人民幣 1.70 億元的結構性存 款產品。 - ...

Core Viewpoint - Fudan Zhangjiang (01349.HK) has entered into agreements with Bank of China to subscribe to structured deposit products totaling RMB 170 million using temporarily idle funds raised from its A-share public offering [1] Related Events - Fudan Zhangjiang (01349.HK) has subscribed to structured deposit products from Bank of China [1] - Fudan Zhangjiang (688505.SH) faced a setback as its drug application for Obecholic Acid Tablets for the treatment of primary biliary cholangitis was not approved [1]

Core Viewpoint - Fudan Zhangjiang (01349) has entered into agreements with Bank of China to subscribe to structured deposit products totaling RMB 170 million using temporarily idle funds raised from its A-share public offering [1] Group 1 - The company has signed two structured deposit product agreements with Bank of China [1] - The total amount for the structured deposit products is RMB 170 million [1] - The funds used for this investment are temporarily idle funds from the company's A-share public offering [1]

Core Viewpoint - Fudan Zhangjiang (01349) has entered into agreements with Bank of China to invest a total of RMB 170 million in structured deposit products using temporarily idle funds raised from the public offering of A-shares [1] Group 1 - The company has signed two structured deposit product agreements with Bank of China [1] - The total amount of investment in these structured deposit products is RMB 170 million [1] - The funds used for this investment are temporarily idle funds from the public offering of A-shares [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購中國銀行結構性存款產品 認購結構性存款產品 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議 I 及中國銀行結構性存款產品協議 II，同意以 A 股公開發行所得暫時閑置募集資金向中國銀行認購總金額為人民幣 1.70 億元的結構 性存款產品。 上市規則的涵義 在訂立中國銀行結構性存款產品協議時，就中國銀行結構性存款產品協議項下產品的認購金額而 言，一項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市 規則第 14 章，该交易構成本公司之須予披露的交易，須遵守上市規則第 14 章有關申報及公告之 規定，惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司與中國銀行訂立中國銀行結構性存款產品協議 I 及中國銀行結構性存款產品協議 II， 同意以 A 股公開發行所得暫時閑置募集資金向中國銀行認購總金額為人民幣 1.70 億元的結構性存 款產品。 - ...